Jovanović Bojana, Sheng Quanhu, Seitz Robert S, Lawrence Kasey D, Morris Stephan W, Thomas Lance R, Hout David R, Schweitzer Brock L, Guo Yan, Pietenpol Jennifer A, Lehmann Brian D
Medical Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School and Broad Institute, Boston, 02215, MA, USA.
Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, 37232, TN, USA.
BMC Cancer. 2017 Apr 4;17(1):241. doi: 10.1186/s12885-017-3237-1.
Triple negative breast cancer (TNBC) is a heterogeneous disease that lacks unifying molecular alterations that can guide therapy decisions. We previously identified distinct molecular subtypes of TNBC (TNBCtype) using gene expression data generated on a microarray platform using frozen tumor specimens. Tumors and cell lines representing the identified subtypes have distinct enrichment in biologically relevant transcripts with differing sensitivity to standard chemotherapies and targeted agents. Since our initial discoveries, RNA-sequencing (RNA-seq) has evolved as a sensitive and quantitative tool to measure transcript abundance.
To demonstrate that TNBC subtypes were similar between platforms, we compared gene expression from matched specimens profiled by both microarray and RNA-seq from The Cancer Genome Atlas (TCGA). In the clinical care of patients with TNBC, tumor specimens collected for diagnostic purposes are processed by formalin fixation and paraffin-embedding (FFPE). Thus, for TNBCtype to eventually have broad and practical clinical utility we performed RNA-seq gene expression and molecular classification comparison between fresh-frozen (FF) and FFPE tumor specimens.
Analysis of TCGA showed consistent subtype calls between 91% of evaluable samples demonstrating conservation of TNBC subtypes across microarray and RNA-seq platforms. We compared RNA-seq performed on 21-paired FF and FFPE TNBC specimens and evaluated genome alignment, transcript coverage, differential transcript enrichment and concordance of TNBC molecular subtype calls. We demonstrate that subtype accuracy between matched FF and FFPE samples increases with sequencing depth and correlation strength to an individual TNBC subtype.
TNBC subtypes were reliably identified from FFPE samples, with highest accuracy if the samples were less than 4 years old and reproducible subtyping increased with sequencing depth. To reproducibly subtype tumors using gene expression, it is critical to select genes that do not vary due to platform type, tissue processing or RNA isolation method. The majority of differentially expressed transcripts between matched FF and FFPE samples could be attributed to transcripts selected for by RNA enrichment method. While differentially expressed transcripts did not impact TNBC subtyping, they will provide guidance on determining which transcripts to avoid when implementing a gene set size reduction strategy.
NCT00930930 07/01/2009.
三阴性乳腺癌(TNBC)是一种异质性疾病,缺乏可指导治疗决策的统一分子改变。我们之前使用在微阵列平台上利用冷冻肿瘤标本生成的基因表达数据,鉴定出了TNBC的不同分子亚型(TNBCtype)。代表所鉴定亚型的肿瘤和细胞系在生物学相关转录本中具有不同程度的富集,对标准化疗和靶向药物的敏感性也不同。自我们最初的发现以来,RNA测序(RNA-seq)已发展成为一种用于测量转录本丰度的灵敏且定量的工具。
为了证明TNBC亚型在不同平台之间具有相似性,我们比较了来自癌症基因组图谱(TCGA)的通过微阵列和RNA-seq分析的匹配标本的基因表达。在TNBC患者的临床护理中,为诊断目的收集的肿瘤标本通过福尔马林固定和石蜡包埋(FFPE)进行处理。因此,为了使TNBCtype最终具有广泛且实用的临床应用价值,我们对新鲜冷冻(FF)和FFPE肿瘤标本进行了RNA-seq基因表达和分子分类比较。
对TCGA的分析显示,91%的可评估样本之间的亚型分类一致,这表明TNBC亚型在微阵列和RNA-seq平台之间具有保守性。我们比较了在21对FF和FFPE TNBC标本上进行的RNA-seq,并评估了基因组比对、转录本覆盖度、差异转录本富集以及TNBC分子亚型分类的一致性。我们证明,匹配的FF和FFPE样本之间的亚型准确性随着测序深度以及与单个TNBC亚型的相关强度而增加。
从FFPE样本中能够可靠地鉴定出TNBC亚型,如果样本年龄小于4年,则准确性最高,并且可重复的亚型分类随着测序深度而增加。为了使用基因表达对肿瘤进行可重复的亚型分类,关键是选择不因平台类型、组织处理或RNA分离方法而变化的基因。匹配的FF和FFPE样本之间大多数差异表达的转录本可归因于RNA富集方法所选择的转录本。虽然差异表达的转录本不影响TNBC亚型分类,但它们将为实施基因集大小缩减策略时确定应避免哪些转录本提供指导。
NCT00930930 2009年7月1日。